Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03608371 · ClinicalTrials.gov registry record · Phase 2
BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations
A Phase 2 study of Parkinson Disease and Motor Disorder, sponsored by BlackThorn Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 4
- Study locations
NCT03608371: Completed Phase 2 study of Parkinson Disease and Motor Disorder, sponsored by BlackThorn Therapeutics.
NCT03608371 is a Phase 2 study of Parkinson Disease and Motor Disorder that has completed, run by BlackThorn Therapeutics. The registered enrollment target is 24 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03608371, a Phase 2 study of Parkinson Disease and Motor Disorder, has completed, sponsored by BlackThorn Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and efficacy of BTRX-246040 in participants with Parkinson's Disease who have motor fluctuations and predictable early morning off periods.
Primary Outcome
UPDRS = Unified Parkinson's Disease Rating Scale. The Unified Parkinson's Disease Rating Scale (UPDRS) Part III is a 14-item rating scale, which consists of the motor examination. Each item is scored from 0 (Normal) to 4 (Most severe). The score ranges from 0-56.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BTRX-246040
Study Locations (4)
Florida
- BlackThorn Investigator Site - Hallandale
Michigan
- BlackThorn Investigator Site - Farmington Hills
North Carolina
- BlackThorn Investigator Site - Durham
Texas
- BlackThorn Investigator Site - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-08-31 |
| Est. Completion | 2019-04-23 |
| Phase | Phase 2 |
What the finished NCT03608371 record still lists
NCT03608371 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03608371 reports a single indexed study location in Florida, Michigan, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03608371 about?
NCT03608371 is a clinical study titled "BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations". The purpose of this study is to assess the safety, tolerability, pharmacokinetics and efficacy of BTRX-246040 in participants with Parkinson's Disease who have motor fluctuations and predictable early morning off periods.
What is the current status of trial NCT03608371?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2018-08-31. Estimated completion is 2019-04-23.
What conditions does trial NCT03608371 study?
This clinical trial studies the following conditions: Parkinson Disease, Motor Disorder.
What interventions are being tested in trial NCT03608371?
The interventions under investigation include: Placebo (DRUG), BTRX-246040 (DRUG).
Who is sponsoring clinical trial NCT03608371?
This trial is sponsored by BlackThorn Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03608371 being conducted?
This trial has 4 study locations across Florida, Michigan, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03608371's enrollment target sits among peer trials
24 232nd of 297 higher than 61 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease
RECRUITING · Phase 2
-
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
RECRUITING · Phase 2
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
RECRUITING · Phase 2
-
Rehabilitation of Airway Protection in Parkinson's Disease
RECRUITING · Phase 2
-
Psilocybin Therapy for Depression in Parkinson's Disease
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI